Robert E. Landry - Dec 10, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Dec 10, 2021
Transactions value $
-$625,837
Form type
4
Date filed
12/14/2021, 03:03 PM
Previous filing
Dec 10, 2021
Next filing
Mar 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $834K +1.5K +5.01% $555.67 31.5K Dec 10, 2021 Direct F1
transaction REGN Common Stock Tax liability -$919K -1.38K -4.4% $664.34 30.1K Dec 10, 2021 Direct F1
transaction REGN Common Stock Tax liability -$463K -697 -2.32% $664.34 29.4K Dec 11, 2021 Direct
transaction REGN Common Stock Sale -$76.9K -116 -0.39% $662.50 29.3K Dec 13, 2021 Direct F1
holding REGN Common Stock 229 Dec 10, 2021 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.5K -37.5% $0.00 2.5K Dec 10, 2021 Common Stock 1.5K $555.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.